Author: Robert MacLaren (United Kingdom)
Co-authors: Jeffrey S. Heier, David H. Steel, Andrew J. Lotery, Peter Charbel Issa, Sobha Sivaprasad, Paulo E. Stanga
Purpose
Complement overactivation has been implicated in age-related macular degeneration (AMD) disease pathogenesis. Complement Factor I (CFI) protein regulates the activity of the complement system, and it is hypothesized that increasing CFI production could dampen the overactive complement system, thereby reducing AMD disease progression. We investigated the safety and dose response of subretinally administered GT005, an investigational recombinant adeno-associated viral (AAV2) vector encoding CFI, for the treatment of geographic atrophy (GA) secondary to AMD.
Setting/Venue
FOCUS (NCT03846193, EudraCT 2017-003712-39) is an ongoing first-in-human, open-label, Phase I/II study conducted at 9 centers in the United States and the United Kingdom. The study consists of 4 parts (dose-escalation/-expansion using transvitreal delivery, and dose-escalation/-expansion using Orbit subretinal delivery system [Orbit SDS]). Interim data from the transvitreal cohorts are presented herein.
Methods
All patients had bilateral GA at baseline. The study eye received a single subretinal administration of GT005. Part 1 explored three GT005 dose levels (2E10, 5E10 and 2E11 vector genomes [vg]) using transvitreal delivery with sentinel dosing between the first and second patient of each dose cohort. Part 2 is ongoing and further explores dose-levels that were shown to be safe and tolerable in Part 1. The primary endpoint is safety over 48 weeks, with secondary endpoints including immunogenicity, vector shedding, anatomical/functional outcomes, and changes in complement protein expression in the vitreous humor.
Results
As of February 2021, 20 patients had received GT005 via transvitreal delivery across Part 1 (n=11) and Part 2 (n=9), with a mean follow-up of 37.6 weeks (range: 1.1 to 94.0 weeks). All dose levels of GT005 were well-tolerated with no dose-related trends in the frequency and type of adverse events (AEs). There were no serious ocular AEs or signs of GT005-related inflammation. AEs of special interest will be presented. The mean change from baseline in best corrected visual acuity in the study eye and the fellow eye at Week 48 was -0.63 (n=8; 95% Confidence Interval [CI]: -8.85, 7.60) and -3.38 (n=8; 95% CI: -9.37, 2.62), respectively. Biomarker analyses showed elevated vitreous CFI levels in 9/10 patients, with an average increase of 146% compared to baseline (p=0.02). Reductions in vitreous Ba and C3 breakdown products were also observed at 24-56 weeks, with an average decrease of 41% and 42% compared to baseline (p-value less than 0.05), respectively. Increases in CFI levels correlated with decreases in Ba levels (R= -0.68, p= 0.03).
Conlusions
GT005 was well tolerated at doses of 2E10 to 2E11vg with no signs of GT005-related inflammation or change from baseline in visual acuity. Biomarker analyses demonstrate durable transgene expression through increased vitreous CFI levels, as well as evidence of target engagement through downstream modulation of complement proteins. FOCUS Parts 2 and 3 are continuing to enroll, and two randomized, controlled Phase II trials (EXPLORE, HORIZON) evaluating the safety and efficacy of GT005 are ongoing.
Financial Disclosure
Research funding and consultancy to Gyroscope Therapeutics Limited (with all fees paid to University of Oxford) and share options that might have future value
Comments
Additional Co-authors: 7. Tsveta Ivanova - Manchester University NHS Foundation Trust, Manchester United Kingdom 8. John Tobin - Gyroscope Therapeutics Limited, London, United Kingdom 9. James Francis - Gyroscope Therapeutics Limited, London, United Kingdom 10. Vedran Pavlovic - Gyroscope Therapeutics Limited, London, United Kingdom 11. Nadia Waheed - Gyroscope Therapeutics Limited, London, United Kingdom